pralnacasan   Click here for help

GtoPdb Ligand ID: 6467

Synonyms: VX-740 | VX740
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Pralnacasan (VX-740) is a selective, non-peptide caspase 1 inhibitor that was developed by Vertex for anti-inflammatory potential. Inhibition of caspase 1 is a small molecule strategy developed as an alternative to the use of anti-IL-1β neutralising antibodies, such as canakinumab, or the dimeric fusion protein rilonacept that acts as a IL-1 trap.
Pralnacasan is a prodrug whose active metabolite is VRT-018858 [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 12
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 147.24
Molecular weight 523.21
XLogP 0.75
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES CCOC1OC(=O)CC1NC(=O)C1CCCN2N1C(=O)C(CCC2=O)NC(=O)c1nccc2c1cccc2
Isomeric SMILES CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN2N1C(=O)[C@H](CCC2=O)NC(=O)c1nccc2c1cccc2
InChI InChI=1S/C26H29N5O7/c1-2-37-26-18(14-21(33)38-26)29-23(34)19-8-5-13-30-20(32)10-9-17(25(36)31(19)30)28-24(35)22-16-7-4-3-6-15(16)11-12-27-22/h3-4,6-7,11-12,17-19,26H,2,5,8-10,13-14H2,1H3,(H,28,35)(H,29,34)/t17-,18-,19-,26+/m0/s1
1. Linton SD. (2005)
Caspase inhibitors: a pharmaceutical industry perspective.
Curr Top Med Chem, 5 (16): 1697-717. [PMID:16375749]
2. Ross J, Brough D, Gibson RM, Loddick SA, Rothwell NJ. (2007)
A selective, non-peptide caspase-1 inhibitor, VRT-018858, markedly reduces brain damage induced by transient ischemia in the rat.
Neuropharmacology, 53 (5): 638-42. [PMID:17845807]
3. Wannamaker W, Davies R, Namchuk M, Pollard J, Ford P, Ku G, Decker C, Charifson P, Weber P, Germann UA et al.. (2007)
(S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18.
J Pharmacol Exp Ther, 321 (2): 509-16. [PMID:17289835]